Background: Isolated common femoral endarterectomy was recently reported to have a 30-day mortality of 3.4%. The effect of adjunctive femoral endarterectomy at the time of lower extremity bypass is not well described, and therefore, the purpose of this study was to determine its associated perioperative and long-term risk.
Endarterectomy has been used to treat peripheral arterial disease for >50 years and is a common adjunctive procedure during lower extremity bypass. The benefit of common femoral endarterectomy has been established, for both inflow and outflow improvements. [1] [2] [3] [4] [5] Some of these studies analyzed isolated common femoral endarterectomy and others reported endarterectomy as part of a hybrid procedure. A recent study from the National Surgical Quality Improvement Program (NSQIP) evaluating isolated common femoral endarterectomy reported a 30-day mortality of 3.4%. 6 Siracuse et al, 7 using NSQIP data from 2007 to 2010, found a 30-day mortality rate of 1.5% for isolated common femoral endarterectomy but differed from the former because it did not include emergency cases. Many of the patients who underwent isolated common femoral endarterectomy, especially in the emergency setting, were likely too sick for a more extensive procedure, such as bypass. Neither NSQIP study analyzed the effect of adjunctive endarterectomy with bypass. Furthermore, bundled Current Procedural Terminology (American Medical Association, Chicago, Ill) coding could complicate this type of analysis using NSQIP data. However, the subset of patients undergoing adjunctive endarterectomy may be at increased perioperative risk in general given the presumably more extensive atherosclerosis that leads to the endarterectomy itself. Quantifying this increased risk for appropriate risk adjustment is important, especially as potential quality metrics for bypass are proposed. Therefore, this study aimed to compare the perioperative and 1-year morbidity and mortality associated with adjunctive femoral endarterectomy in lower extremity bypass using data from the Vascular Study Group of New England (VSGNE).
METHODS
We performed a retrospective cohort study of all patients undergoing lower extremity bypass in the VSGNE from 2003 through 2015 (N ¼ 9144 operations). VSGNE is a prospectively collected clinical registry created by vascular surgeons in New England that collects short-term and long-term data on all patients from participating hospitals with the aim or improving regional outcomes. Data in the VSGNE are collected by the surgeon and trained nurses or clinical abstractors, as described previously, on >100 clinical and demographic variables. 8 The Beth Israel Deaconess Medical
Center Institutional Review Board approved this study and waived informed consent due to the use of deidentified data.
Patients and cohorts. Of the 9144 operations identified, only a patient's initial procedure in the registry was used to create our cohorts, thus excluding 1398 subsequent contralateral and ipsilateral operations. From the 7746 patients, we excluded all emergency (n ¼ 276), asymptomatic, or acute limb ischemia indications (n ¼ 960), and any bypasses that did not originate in the common femoral or profunda femoris arteries (n ¼ 1950). The VSGNE has a surgeon-entered variable specifying whether a concurrent proximal ipsilateral endarterectomy was performed with the bypass, which was used to create our cohorts. There was a clear reporting change in 2009, with 1.6% (n ¼ 49) of patients missing data on adjunctive endarterectomy in the later period compared with 64% before 2009. Those missing endarterectomy data before 2009 were presumed to have not undergone an adjunctive endarterectomy. The Fig illustrates the steady rate of adjunctive endarterectomy after this assumption was made.
After the 49 patients missing this variable from 2009 to 2015 were excluded, we were left with 4496 patients undergoing a bypass. We performed a sensitivity analysis on years 2009 to 2015 using the same models for adjustment at 30 days and 1 year for all end points discussed and found similar results. The purpose of our analysis was to evaluate the associated risk in patients undergoing adjunctive endarterectomy, and so we felt it more important to keep patients before 2009 in this study, and perform a sensitivity analysis, in order to have as much power as possible to detect a difference, rather than just focus the entire study on the 2009 to 2015 cohort. A case was considered urgent in the VSGNE if nonelective surgery occurred 12 to 72 hours after admission. Outside of mortality, all perioperative outcomes reported are for in-hospital adverse events owing to the limits of the registry, and similarly, all long-term outcomes represent 1-year results.
Renal function deterioration was defined as a >0.5 mg/dL increase from the baseline creatinine measurement or new dialysis. Prolonged postoperative length of stay was defined as discharge >7 days after the bypass. A major adverse limb event was defined as subsequent thrombectomy, lysis, or revision of bypass, or major ipsilateral amputation. Major ipsilateral amputation included above-knee and below-knee major amputation. The registry does not distinguish between these at 1 year. Adjusted analyses for in-hospital adverse events were performed using multivariable logistic regression analysis. Owing to limited event numbers, multivariable models were combined and adjusted for patients with claudication and CLI symptoms. Purposeful selection was used to populate these models (using significance of P < .10 for initial inclusion as well as important covariates from prior studies) to test for the independent association of adjunctive endarterectomy with outcomes of interest. 9 Event rates were listed for perioperative and 1-year outcomes to demonstrate each model had an adequate number of adverse events to allow for inclusion of adjusted for confounders. 10 Our sensitivity analysis used all variables identified in the overall models to adjust for the same potential confounders. Operative time was not included in the models because of collinearity with surgery type. Only patients eligible for 1-year follow-up were included for long-term analysis. Eligibility was defined as a patient with an operative date $9 months before the date of data extraction, which for our analysis was August 2015. For 1-year end points, we used the previously published definitions from the Society for Vascular Surgery and performed time-to-event analysis using Kaplan-Meier and life- Operative details. Only lower extremity bypasses originating from the common femoral and profunda femoris were included. There was no difference in proportion with profunda origin between groups (Table II) . Total operative time was longer with adjunctive femoral endarterectomy (median, 268 [IQR, 200-338] minutes vs 210 [IQR, 160-283] minutes; P < .001), although 43% of patients were missing this information. When restricted to 2009 to 2015, only 15% of patients were missing operative time, and the same difference remained. This operative time difference persisted when patients undergoing any concurrent endovascular or suprainguinal bypass procedures were excluded (overall: 256 minutes vs 206 minutes, P < .001; CLI: 266 minutes vs 223 minutes, P < .001; claudication: 233 minutes vs 184 minutes, P < .001). Bypass with endarterectomy also had higher estimated blood loss (median, 250 mL vs 180 mL; P < .001) and a greater proportion undergoing concurrent endovascular intervention (14% vs 6%; P < .001), although 21% were missing these data.
Perioperative outcomes. The overall 30-day mortality rate was similar between the adjunctive endarterectomy and bypass-only cohorts (1.8% vs 2.1%; P ¼ .60). In patients with CLI, in-hospital mortality and 30-day mortality were similar between bypass with endarterectomy (2.0% vs 1.5%; P ¼ .32) and without endarterectomy (2.6% vs 2.9%; P ¼ .61; Table III, A). Patients with CLI undergoing adjunctive endarterectomy had higher rates of postoperative myocardial infarction (MI; 6.2% vs 3.8%; P ¼ .003) and transfusion of >2 units of packed red blood cells (11% vs 6.8%; P < .001). They were also more likely to be discharged on an antiplatelet and statin regimen (76% vs 71%; P ¼ .01). Renal function deterioration, major ipsilateral amputation, surgical site infections (SSIs), and primary patency were similar at discharge. Despite higher rates of transfusion, there was also no difference in return to the operating room (12% vs 14%; P ¼ .44) or in prolonged postoperative length of stay (7.5% vs 5.2%; P ¼ .08) between bypass with adjunctive endarterectomy and without, respectively.
For patients with claudication, there were few deaths overall and, again, no difference between patients undergoing bypass with and without endarterectomy for in-hospital (0.2% vs 0.2%; P ¼ 1.0) or 30-day mortality (0.2% vs 0.4%; P ¼ 1.0; Table III, B). Those undergoing adjunctive endarterectomy had higher rates of MI (2.4% vs 0.9%; P ¼ .02), renal function deterioration (3.6% vs 1.4%; P ¼ .01), SSIs (5.0% vs 2.6%; P ¼ .02), and transfusions of >2 units (4.6% vs 1.8%; P ¼ .002). There was no difference in major ipsilateral amputation, primary patency at discharge, prolonged postoperative length of stay, or antiplatelet and statin combination at discharge.
Multivariable analysis showed that bypass with endarterectomy was associated with an increased risk of MI (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.09-2.2; Table IV ). This same model was run without adjusting for transfusion to demonstrate the degree of interaction between transfusion and MI, with a similar independent association between adjunctive endarterectomy and MI (OR, 1.6; 95% CI, 1.1-2.2). Bypass with endarterectomy was also independently associated with an increased risk for SSIs (OR, 1.5; 95% CI, 1.1-2.0) and transfusion of >2 units (OR, 1.8; 95% CI, 1.4-2.3). There was no difference in risk for 30-day mortality (OR, 0.87; 95% CI, 0.54-1.4) or renal dysfunction (OR, 1.2; 95% CI, 0.83-1.7) between groups.
Outcomes at 1 year. Overall there was no difference in the proportion eligible for 1-year follow-up between the bypass cohorts with and without endarterectomy (83% vs 84%; P ¼ . respectively; P ¼ .30). Table V reports the unadjusted Kaplan-Meier event rates and associated log-rank P values stratified by symptom status as well as the unadjusted and adjusted Cox hazard ratios (HRs) without stratification and for CLI alone. There were too few events in the claudication group to adjust for differences separately. Survival at 1 year was similar among patients with claudication (97% vs 96%; P ¼ .36) and CLI (85% vs 83%; P ¼ .15). Patients undergoing a bypass with endarterectomy for CLI had improved 1-year freedom from major amputation (91% vs 87%; P ¼ .049) and 1-year amputation-free survival (AFS; 80% vs 76%; P ¼ .03) compared with those not undergoing endarterectomy.
When adjusting for all relevant preoperative differences, we found no association between adjunctive endarterectomy and mortality (HR, 0.9; 95% CI, 0.7-1.1), AFS (HR, 0.8; 95% CI, 0.7-1.01), major amputation (HR, 0.8; 95% CI, 0.5-1.1), or major adverse limb event (HR, 1.0; 95% CI, 0.9-1.2) at 1 year (Table V; Supplementary  Table [ online only] for full Cox proportional hazard models). When these same end points were limited to patients with CLI only, there again was no difference between our cohorts at 1 year. Our sensitivity analysis, limiting years to 2009 to 2015, had no effect on our adjusted findings, although the univariate benefit to endarterectomy seen in all years for patients with CLI, with respect to 1-year freedom from major amputation (91% vs 87%; P ¼ .09) and AFS (81% vs 77%; P ¼ .12), did not reach significance.
DISCUSSION
This study demonstrates that patients undergoing adjunctive femoral endarterectomy with lower extremity bypass have similar mortality to those undergoing bypass alone, both in the perioperative period and at 1-year. Performance of an endarterectomy with bypass does, however, appear to be independently associated with postoperative MI, need for transfusions of >2 units, and SSIs. However, there was a suggestion of potential limb benefit with endarterectomy in 1-year freedom from major amputation and AFS.
Our 30-day mortality rate of 1.8% for those undergoing bypass with endarterectomy was similar to the 1.2% reported by Malgor et al, 5 which consisted of 85 patients with adjunctive femoral endarterectomy, 40% of whom had claudication. This same study also reported a similar 1-year survival to ours of 84% vs 89%. Interestingly, Malgor et al 5 also found that isolated common femoral endarterectomy had a 1.4% 30-day mortality rate (67% of whom had claudication) compared with the 3.4% reported by Nguyen et al, 6 although the later study had a larger sample size, 13% emergency cases, and 29% with rest pain. However, the overall proportion with CLI could not be determined in the later study owing to limits of the registry used. For comparison, a second study using a similar NSQIP sample to Nguyen et al, but excluding emergency cases, reported a 30-day mortality of 1.5% after isolated common femoral endarterectomy. 7 The later study did not identify the proportion of patients with rest pain, and as mentioned, could not identify the proportion with CLI. We think it is the emergency cases that carry higher mortality risk, and which led Nguyen et al 6 to report a 3.4% mortality rate for isolated femoral endarterectomy, whereas our study, which excluded emergency cases, is more consistent with prior literature using similar populations. Patients with CLI undergoing adjunctive endarterectomy had improved 1-year AFS and freedom from major amputation on Kaplan-Meier analysis in our study. It is possible that the addition of an endarterectomy helps keep the foot perfused through the profunda and collaterals when the bypass goes down, compared with those patients who did not undergo an adjunctive endarterectomy, and that this results in better limb salvage. Antiplatelet and statin medications were prescribed more commonly in the endarterectomy group preoperatively and at discharge. When this was accounted for in our adjusted Cox regression, there was a dampening of the effect of endarterectomy. Despite this, our CI only just crosses 1.0 for AFS and freedom from major amputation, making the significant results on univariate testing less likely to be a false positive. Therefore, further investigation is warranted.
Our study found significant differences in operative time, estimated blood loss, and transfusions administered between patients undergoing adjunctive endarterectomy and bypass alone. After additional concurrent procedures were excluded, adjunctive endarterectomy added w45 minutes to a lower extremity bypass, regardless of symptoms. Using the Vascular Quality Initiative national registry, Kalish et al 12 reported an SSI rate of 4.8% for lower extremity bypass, and found that an ankle-brachial index <0.35, operative time >220 minutes, estimated blood loss >100 mL, and transfusion of >2 units were predictive of SSIs. Given these data, the higher rate of SSIs we saw in the endarterectomy group is not surprising. Our SSI rate of 5.4% was slightly higher than reported by Kalish et al 12 for patients with groin incisions, likely because we included only patients with bypasses originating in the common femoral artery and profunda but not the superficial femoral artery. We also found a nearly twofold increased rate of cardiac events in the endarterectomy group that persisted even after adjustment for preoperative differences. Malgor et al 5 also found similar rates of MI (5%) and dysrhythmia (5%) in their 85 patients who underwent endarterectomy with bypass. This could be related to the higher estimated blood loss and prolonged operative time in those undergoing adjunctive endarterectomy. In addition, vascular patients in general are at increased risk for MI postoperatively, but the difference reported in our analysis could be explained further by the increased atherosclerotic burden and likely increased coronary vascular disease for those selected to undergo an adjunctive endarterectomy, presumably for plaque-laden arteries. In addition, we report a significantly higher rate of prior coronary artery bypass grafting or percutaneous coronary intervention in patients undergoing adjunctive endarterectomy, which further supports the likelihood of more clinically aggressive atherosclerotic disease in the adjunctive endarterectomy group. There were no differences in reported rates of coronary artery disease or congestive heart failure, although we do know from prior reports that large proportions of vascular patients have undiagnosed but significant coronary disease, which may further explain the high rates of cardiac complications in the adjunctive endarterectomy group, which we presume to have greater atherosclerotic burden, despite similar coronary artery disease and congestive heart failure rates. 13 Both cohorts in our study had similarly small proportions of concurrent suprainguinal bypasses but a large difference in concurrent proximal endovascular interventions, with higher rates in the adjunctive endarterectomy group. Prior studies have proven the efficacy of iliac angioplasty and stenting in patients with inflow disease, and we believe the higher rate of proximal endovascular intervention is a reflection of the increased atherosclerotic burden in patients undergoing adjunctive endarterectomy. 3 Limitations of this study include those inherent in any retrospective analysis, such as misreporting and missing data. However, a major strength of the VSGNE data is that the surgeon fills out the operative details for each patient, making these data reliable and specific. Also, we handled missing data by focusing our 1-year outcomes discussion on time-to-event analysis using an accepted standard error rate of <0.10, which adequately accounts for missing data by censoring and indicates the time point our sample size becomes too small to perform reliable analyses, although this does not account for nonrandom censoring.
Furthermore, we were unable to distinguish between the simple endarterectomy performed for debulking at the time of anastomosis and the more extensive endarterectomy that results in patch repair before graft anastomosis. It is likely that this latter group drove the increased risk for perioperative events and longer operative time, but this could not be proven. We were also unable to distinguish whether the SSI was at the level of the endarterectomy or at other incisions related to the bypass. Endarterectomy could theoretically protect against SSI below the groin by improving blood flow but could also increase SSI, both at the groin and more distally, through interruption of lymphatics.
In addition, this study does not have the appropriate data to imply a causal relationship between adjunctive endarterectomy and higher rates of MI and SSIs. We believe a surgeon's decision to perform an adjunct endarterectomy is likely a marker of a patient with more systemic disease, and it is important to demonstrate that adjunctive femoral endarterectomy with lower extremity bypass is safe despite a recent report of high perioperative mortality in isolated common femoral endarterectomy. Bold values indicate statistical significance. c There were too few events in claudication group to stratify analysis, so symptom status was included in the adjustment and overall HR with respect to adjunct endarterectomy. The CLI only HRs are therefore similar to overall. Adjusted for age (decades), gender, race (white vs nonwhite), preoperative renal dysfunction (creatinine >1.78 mg/dL), smoker, diabetes, coronary artery disease, prior coronary artery bypass grafting/percutaneous coronary intervention, congestive heart failure, chronic obstructive pulmonary disease, history of lower extremity bypass, symptoms (claudication, rest pain, tissue loss), postoperative in-hospital ipsilateral major amputation (only included in the survival model), and discharged on antiplatelet and statin medication.
CONCLUSIONS
Adjunctive femoral endarterectomy with bypass does not lead to an increased perioperative or 1-year mortality risk despite increased in-hospital MIs, transfusions, and SSIs. The practicing surgeon should not hesitate to perform an adjunctive endarterectomy in appropriate patients but should be aware of the higher perioperative risk associated with patients undergoing this procedure and take precautions to minimize these complications. The possibility of a benefit for 1-year AFS and freedom from major amputation, as reported in this analysis, with adjunctive endarterectomy when deemed clinically appropriate, warrants further study. 
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